323 related articles for article (PubMed ID: 14596938)
1. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
Paugh SW; Payne SG; Barbour SE; Milstien S; Spiegel S
FEBS Lett; 2003 Nov; 554(1-2):189-93. PubMed ID: 14596938
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases.
Billich A; Bornancin F; Dévay P; Mechtcheriakova D; Urtz N; Baumruker T
J Biol Chem; 2003 Nov; 278(48):47408-15. PubMed ID: 13129923
[TBL] [Abstract][Full Text] [Related]
3. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.
Zemann B; Kinzel B; Müller M; Reuschel R; Mechtcheriakova D; Urtz N; Bornancin F; Baumruker T; Billich A
Blood; 2006 Feb; 107(4):1454-8. PubMed ID: 16223773
[TBL] [Abstract][Full Text] [Related]
4. Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells.
Nagaoka Y; Otsuki K; Fujita T; Uesato S
Biol Pharm Bull; 2008 Jun; 31(6):1177-81. PubMed ID: 18520051
[TBL] [Abstract][Full Text] [Related]
5. Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
Don AS; Martinez-Lamenca C; Webb WR; Proia RL; Roberts E; Rosen H
J Biol Chem; 2007 May; 282(21):15833-42. PubMed ID: 17400555
[TBL] [Abstract][Full Text] [Related]
6. FTY720 postconditions isolated perfused heart by a mechanism independent of sphingosine kinase 2 and different from S1P or ischemic postconditioning.
Vessey DA; Li L; Imhof I; Honbo N; Karliner JS
Med Sci Monit Basic Res; 2013 Apr; 19():126-32. PubMed ID: 23567658
[TBL] [Abstract][Full Text] [Related]
7. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720.
Allende ML; Sasaki T; Kawai H; Olivera A; Mi Y; van Echten-Deckert G; Hajdu R; Rosenbach M; Keohane CA; Mandala S; Spiegel S; Proia RL
J Biol Chem; 2004 Dec; 279(50):52487-92. PubMed ID: 15459201
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.
Butler J; Lana D; Round O; LaMontagne K
Prostaglandins Other Lipid Mediat; 2004 Jan; 73(1-2):29-45. PubMed ID: 15165029
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720.
Kharel Y; Lee S; Snyder AH; Sheasley-O'neill SL; Morris MA; Setiady Y; Zhu R; Zigler MA; Burcin TL; Ley K; Tung KS; Engelhard VH; Macdonald TL; Pearson-White S; Lynch KR
J Biol Chem; 2005 Nov; 280(44):36865-72. PubMed ID: 16093248
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability.
Sanchez T; Estrada-Hernandez T; Paik JH; Wu MT; Venkataraman K; Brinkmann V; Claffey K; Hla T
J Biol Chem; 2003 Nov; 278(47):47281-90. PubMed ID: 12954648
[TBL] [Abstract][Full Text] [Related]
11. FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells.
Berdyshev EV; Gorshkova I; Skobeleva A; Bittman R; Lu X; Dudek SM; Mirzapoiazova T; Garcia JG; Natarajan V
J Biol Chem; 2009 Feb; 284(9):5467-77. PubMed ID: 19119142
[TBL] [Abstract][Full Text] [Related]
12. The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Brinkmann V; Davis MD; Heise CE; Albert R; Cottens S; Hof R; Bruns C; Prieschl E; Baumruker T; Hiestand P; Foster CA; Zollinger M; Lynch KR
J Biol Chem; 2002 Jun; 277(24):21453-7. PubMed ID: 11967257
[TBL] [Abstract][Full Text] [Related]
13. Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory.
Hait NC; Wise LE; Allegood JC; O'Brien M; Avni D; Reeves TM; Knapp PE; Lu J; Luo C; Miles MF; Milstien S; Lichtman AH; Spiegel S
Nat Neurosci; 2014 Jul; 17(7):971-80. PubMed ID: 24859201
[TBL] [Abstract][Full Text] [Related]
14. Molecular targets of FTY720 (fingolimod).
Pitman MR; Woodcock JM; Lopez AF; Pitson SM
Curr Mol Med; 2012 Dec; 12(10):1207-19. PubMed ID: 22834825
[TBL] [Abstract][Full Text] [Related]
15. Targeting sphingosine-1-phosphate in hematologic malignancies.
Stevenson CE; Takabe K; Nagahashi M; Milstien S; Spiegel S
Anticancer Agents Med Chem; 2011 Nov; 11(9):794-8. PubMed ID: 21707492
[TBL] [Abstract][Full Text] [Related]
16. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.
Pchejetski D; Bohler T; Brizuela L; Sauer L; Doumerc N; Golzio M; Salunkhe V; Teissié J; Malavaud B; Waxman J; Cuvillier O
Cancer Res; 2010 Nov; 70(21):8651-61. PubMed ID: 20959468
[TBL] [Abstract][Full Text] [Related]
17. Role of the sphingosine metabolism pathway on neurons against experimental cerebral ischemia in rats.
Hasegawa Y; Suzuki H; Altay O; Rolland W; Zhang JH
Transl Stroke Res; 2013 Oct; 4(5):524-32. PubMed ID: 24187597
[TBL] [Abstract][Full Text] [Related]
18. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors.
Payne SG; Oskeritzian CA; Griffiths R; Subramanian P; Barbour SE; Chalfant CE; Milstien S; Spiegel S
Blood; 2007 Feb; 109(3):1077-85. PubMed ID: 17008548
[TBL] [Abstract][Full Text] [Related]
19. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.
Hisano Y; Kobayashi N; Kawahara A; Yamaguchi A; Nishi T
J Biol Chem; 2011 Jan; 286(3):1758-66. PubMed ID: 21084291
[TBL] [Abstract][Full Text] [Related]
20. The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity.
Bandhuvula P; Tam YY; Oskouian B; Saba JD
J Biol Chem; 2005 Oct; 280(40):33697-700. PubMed ID: 16118221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
